Core Viewpoint - Haizheng Pharmaceutical announced that its subsidiary, Haizheng Animal Health, received approval from the Ministry of Agriculture and Rural Affairs for two veterinary drug products, which will enhance the company's product line in animal medicine [1] Group 1: Product Approvals - The approved products include Compound Streptomycin Ointment, valid from September 5, 2025, to September 4, 2030, for treating external ear infections in dogs and cats [1] - The second product, Tocilizumab Suspension, is approved for use from October 24, 2025, to October 23, 2030, aimed at preventing coccidiosis in piglets and calves [1] Group 2: Market Impact - The approval of these products will enrich the company's veterinary drug portfolio, although the market launch and sales are subject to uncertainties related to policies and market conditions [1]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its veterinary drug products, which will enhance its product line and market competitiveness in the veterinary sector [1] Group 1 - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has obtained approval for the compound griseofulvin ointment and torasemide suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure [1] - This development is expected to further promote the company's strategic layout in the veterinary drug sector [1]

Meeting Overview - The company will hold its second extraordinary general meeting of shareholders in 2025 on November 12, 2025, at 1:00 PM [2] - The meeting will be convened by the Board of Directors following the eighth meeting of the tenth Board [2] Voting Method - The voting will be conducted through a combination of on-site and online voting [3] - On-site voting will take place at the company's conference room located at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province [3] - Online voting will be available via the Shanghai Stock Exchange's shareholder meeting voting system on the same day, with specific time slots for trading system and internet platform voting [3] Meeting Agenda - The meeting will review proposals that have already been approved by the eighth meeting of the tenth Board of Directors [6] - There are no special resolutions or proposals requiring separate voting for minority investors [7] Attendance - Shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch after the close of trading on the registration date are entitled to attend the meeting [10] - The meeting will also be attended by the company's directors, senior management, and appointed lawyers [11][12] Registration Process - Registration for attendance requires specific documentation depending on the type of shareholder, with a registration period set for November 10, 2025 [13][14] - Remote shareholders can register via mail or fax [15] Additional Information - The meeting will last half a day, and attendees are responsible for their own travel and accommodation [16] - The company will utilize a reminder service to notify shareholders about the meeting and voting options [16] - Contact information for inquiries is provided, including phone and fax numbers [16]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600267 证券简称：海正药业 公告编号：临2025-66号 浙江海正药业股份有限公司 关于召开2025年第二次临时股东会的提示性公告 重要内容提示： 浙江海正药业股份有限公司（以下简称"公司"）于2025年10月28日在《中国 证券报》《上海证券报》《证券时报》和上海证券交易所网站（www.sse.com.cn） 上刊登了《浙江海正药业股份有限公司关于召开2025年第二次临时股东会的通 知》（公告编号：临2025-63号）。本次股东会采用现场和网络投票相结合的方 式召开，现发布本次临时股东会提示性公告。 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第二次临时股东会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 11 月 12 日 13 点 00 分 召开地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路 46 号） (五)网络投票的系统、起止日期和投票时间。 股东会召开日期：2025年11月12日 本次股东会采用的网络投票 ...

浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 二○二五年十一月十二日 浙江海正药业股份有限公司 2025 年第二次临时股东会会议资料 会议议程 时间：2025 年 11 月 12 日（周三）13:00，会期半天 地点：浙江海正药业股份有限公司（以下简称"公司"或"海正药业"）会议室（台 州市椒江区外沙路 46 号） 主要议程： 一、宣布会议开始并宣布到会代表资格审查结果 二、审议下列议案 | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于拟参与浙江圣兆药物科技股份有限公司股票定向发行及与其共同投 | | | 资设立复杂注射剂合资公司的议案 | 上述议案已经公司第十届董事会第八次会议审议通过，具体内容详见 2025 年 10 月 28 日的《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 （www.sse.com.cn）。 三、股东及其授权代表发言及答疑 四、对上述各议案进行投票表决 五、统计有效表决票 六、宣布表决结果 2 1、总监票组织监票小组 2、股东及股东代表投 ...

Core Insights - The "2025 Entrepreneur Conference" emphasizes the importance of high-level openness and innovation for businesses to seize historical opportunities and responsibilities [1][3] - The pharmaceutical industry is directed towards high-quality development, with a focus on innovation as a core principle for companies like Haizheng Pharmaceutical [5] Group 1: Company Strategy - Haizheng Pharmaceutical is enhancing its innovation capabilities by focusing on "from 0 to 1" drug development and adhering to international quality standards [3] - The company is adopting a "comprehensive internationalization" strategy, viewing the global market as a whole and leveraging domestic competitive advantages [3] Group 2: Innovation and Development - Haizheng has prioritized areas such as AI-assisted research, small nucleic acids, synthetic biology, and high-end formulations, supported by a strategic scientific advisory committee [5] - The company is implementing a dual-track development strategy, accelerating innovative drug research and optimizing generic drug processes to enhance cost and quality advantages [5] Group 3: Market Expansion and Brand Building - Haizheng is diversifying into pet care, medical aesthetics, and health sectors to strengthen market resilience and ensure high-quality development [5] - The company is committed to quality control and continuous innovation to build a trusted "Haizheng Manufacturing" brand while fulfilling social responsibilities [5] Group 4: Entrepreneurial Spirit - The new era of entrepreneurship requires a fearless and persistent approach to explore and deepen in the pharmaceutical industry, contributing to the health of the nation [5]

Core Viewpoint - On November 3, 2023, the company announced that it has repurchased a total of 580,000 shares through centralized bidding, representing 0.05% of the company's total share capital [2] Summary by Category Company Actions - The company has conducted a share repurchase, accumulating 580,000 shares [2] - The repurchased shares account for 0.05% of the total share capital [2]

证券代码：600267 证券简称：海正药业 公告编号：临 2025-65 号 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 5 | 12 | 日~2026 | 年 | 月 | 日 11 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 6,115,000股 | | | | | | | 累计已回购股数占总股本比例 | 0.51% | | | | | | | 累计已回购金额 | 56,991,520元 | | | | | | | 实际回购价格区间 | 8.92元/股~10.55元/股 | | | | | | 一、 回购股份的基本情况 浙江海正药业股份有限公司（以下简称"公司"）于 2025 年 5 月 12 日召开 ...

Summary of Key Points Core Viewpoint - Haizheng Pharmaceutical announced on November 3 that as of the end of October 2025, the company has repurchased approximately 6.12 million shares, accounting for 0.51% of the total share capital, with a total expenditure of about 56.99 million yuan [1] Company Actions - The maximum purchase price for the repurchased shares was 10.55 yuan per share, while the minimum purchase price was 8.92 yuan per share [1]

Core Viewpoint - The company, Haizheng Pharmaceutical, announced its fourth share repurchase plan, which will commence on May 12, 2025, and is expected to last until May 11, 2026, with a budget of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] Summary by Categories Share Repurchase Plan - The company plans to repurchase shares through centralized bidding, with a total expected amount of 50 million to 100 million yuan [1] - The repurchase period is set from May 12, 2025, to May 11, 2026 [1] Current Repurchase Status - As of the end of October 2025, the company has repurchased a total of 6,115,000 shares, which accounts for 0.51% of the total share capital [1] - The total amount spent on repurchases so far is 56.9915 million yuan, with repurchase prices ranging from 8.92 yuan to 10.55 yuan per share [1]